Department of Labor Proposes New PBM Fee Disclosure Requirements for Self-Insured Health Plans
By: Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh PBM compensation structures may soon face new federal transparency requirements. In […]
The Audit That Pays for Itself: Why Reviewing Your PBM’s Performance Isn’t Optional
By: Kevin Kobielski, President of Navion Pharmacy benefit managers often offer appealing guarantees—rebates, discounts, and price protections among some of them. But
Q4 2025 Drug Landscape: New FDA Approvals, Label Changes, and Biosimilars
By Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh Q4 2025 brings meaningful FDA activity across high-cost therapeutic areas, along
Making Sense of MAP, PAP, and CAP Programs
By: Kevin Kobielski, President of Navion As specialty drug costs continue to rise, alternative funding programs like Manufacturer Assistance Programs
Breaking Down Outpatient Infusion Costs: Billing, Site of Care and Savings Paths
By Jason Peterson, RPh and Beckie Fenrick, PharmD, MBA Infused and injectable therapies play a critical role in treating complex conditions, but they also represent some of
Why PBM Contracts That Look Good on Paper Can Cost You More in Reality
By: Kevin Kobielski, President of Navion At first glance, many pharmacy benefit proposals can feel impressive—thick with rebate guarantees, discount percentages, and
Precision Medicine in Practice: The Growing Value of Pharmacogenomic (PGx) Testing
By Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh As pharmacy costs climb and personalization reshapes every corner of healthcare,
